Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | CA2 | P00918 | 2/20 | 0.82 |
| ▸ | CA12 | O43570 | 1/20 | 0.82 |
| ▸ | CA9 | Q16790 | 1/20 | 0.82 |
| ▸ | PGR | P06401 | 6/20 | 0.70 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.61 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.61 |
| ▸ | CA1 | P00915 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | IL1RN | P18510 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2242888 | 0.91 | CA2 (1.00) | MEN1KMT2AMAPK1SMN1; SMN2LMNA | |
| SCHEMBL9231028 | 0.87 | PGR (0.83) | MEN1KMT2AMAPK1SMN1; SMN2LMNA | |
| SCHEMBL1471804 | 0.86 | PGR (0.79) | MEN1KMT2AMAPK1SMN1; SMN2LMNA | |
| SCHEMBL4823249 | 0.86 | CA2 (0.90) | MEN1KMT2AMAPK1SMN1; SMN2LMNA | |
| SCHEMBL12167642 | 0.86 | LMNA (0.75) | MEN1KMT2AMAPK1SMN1; SMN2LMNA | |
| SCHEMBL1472101 | 0.84 | MEN1 (0.72) | MEN1KMT2AMAPK1SMN1; SMN2LMNA | |
| SCHEMBL1471227 | 0.84 | MAPT (0.72) | MEN1KMT2AMAPK1SMN1; SMN2LMNA | |
| SCHEMBL12011009 | 0.83 | KMT2A (0.70) | MEN1KMT2AMAPK1SMN1; SMN2LMNA | |
| SCHEMBL7498033 | 0.82 | CA2 (0.83) | MEN1KMT2AMAPK1SMN1; SMN2LMNA | |
| SCHEMBL4203669 | 0.81 | PGR (0.96) | MEN1KMT2AMAPK1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915293-B2 | Carbocyclic and heterocyclic sulfonamide derivatives, e.g., N-(2-bromo-5-(trifluoromethoxy)phenyl)-3,5-dichloro-4-(2-chloro-4-nitrophenoxy)benzenesulfonamide and 4-(2-(trifluoromethyl)phenoxy)-1-(3-trifluoromethyl)phenylsulfonyl)piperidine; treating proliferative diseases | RIGEL PHARMACEUTICALS, INC. (US) | 2011-03-29 | — | — | US | claimed |
| US-20050009871-A1 | Ubiquitin ligase inhibitors | RIGEL PHARMACEUTICALS, INC. | 2005-01-13 | — | — | US | claimed |
| US-7915293-B2 | Carbocyclic and heterocyclic sulfonamide derivatives, e.g., N-(2-bromo-5-(trifluoromethoxy)phenyl)-3,5-dichloro-4-(2-chloro-4-nitrophenoxy)benzenesulfonamide and 4-(2-(trifluoromethyl)phenoxy)-1-(3-trifluoromethyl)phenylsulfonyl)piperidine; treating proliferative diseases | RIGEL PHARMACEUTICALS, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-20050009871-A1 | Ubiquitin ligase inhibitors | RIGEL PHARMACEUTICALS, INC. | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009871-A1 | Ubiquitin ligase inhibitors | NEDD4, STUB1, UBE3A | MEN1 3441/4885KMT2A 1014/4885MAPK1 2781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.